TRML (Tourmaline Bio) FCF Yield % : -23.45 (As of Apr. 05, 2025)

View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Tourmaline Bio's Trailing 12-Month Free Cash Flow is $-77.26 Mil, and Market Cap is $329.54 Mil. Therefore, Tourmaline Bio's FCF Yield % for today is -23.45%.

The historical rank and industry rank for Tourmaline Bio's FCF Yield % or its related term are showing as below:

TRML' s FCF Yield % Range Over the Past 10 Years
Min: -23.59 Med: 0 Max: 0
Current: -23.45

TRML's FCF Yield % is ranked worse than
57.78% of 1497 companies
in the Biotechnology industry
Industry Median: -15.53 vs TRML: -23.45

Tourmaline Bio's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

Tourmaline Bio FCF Yield % Historical Data

The historical data trend for Tourmaline Bio's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tourmaline Bio FCF Yield % Chart

Tourmaline Bio Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

FCF Yield %

-5.28

-14.87

Tourmaline Bio Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial							-7.03	-10.16	-21.84	-14.22	-16.08

Competitive Comparison of Tourmaline Bio's FCF Yield %

For the Biotechnology subindustry, Tourmaline Bio's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's FCF Yield % falls into.

Save Embed

;

Save Embed

;

Tourmaline Bio FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Tourmaline Bio's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-77.272	/	519.53304
	=	-14.87%

Tourmaline Bio's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-20.889	*	4	/	519.53304
	=	-16.08%

Tourmaline Bio FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Tourmaline Bio FCF Yield % Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

27 West 24th Street, Suite 702, New York, NY, USA, 10010

Website

https://www.tourmalinebio.com

Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.